CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a phase II clinical trial in patients with metastatic castration sensitive prostate
cancer. The objective of the study is to determine the efficacy and further define the safety
of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with
cabazitaxel 20 mg/m2. Patients will be treated with the combination of ADT and carboplatin
and cabazitaxel for 6 cycles. After 6 cycles of chemotherapy, they will start abiraterone
with ADT. The primary objective is to determine the percent of subjects that have no PSA or
radiographic progression at 1 year. Secondary objectives will include determining the
progression-free survival, time to PSA nadir and time to PSA progression of carboplatin and
cabazitaxel in combination with ADT.